

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 October 2022 (06.10.2022)



(10) International Publication Number
WO 2022/212231 A2

(51) International Patent Classification:
C12N 15/113 (2010.01) A61P 25/28 (2006.01)
A61K 31/713 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2022/022093

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:
28 March 2022 (28.03.2022)

(25) Filing Language: English

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(26) Publication Language: English

(30) Priority Data:
63/167,140 29 March 2021 (29.03.2021) US

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.**
[US/US]; 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, MA 02142 (US).

(72) Inventors: **SOUNDARAPANDIAN, Mangala,**
Meenakshi; 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, MA 02142 (US). **MCININCH, James,**
D.; 675 West Kendall Street, Henri A. Termeer Square,
Cambridge, MA 02142 (US). **SCHLEGEL, Mark, K.;**
675 West Kendall Street, Henri A. Termeer Square, Cam-
bridge, MA 02142 (US). **CASTORENO, Adam;** 675 West
Kendall Street, Henri A. Termeer Square, Cambridge, MA
02142 (US).

(74) Agent: **ZACHARAKIS, Maria, Laccotripe et al.;** Mc-
Carter & English, LLP, 265 Franklin Street, Boston, MA
02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: HUNTINGTIN (HTT) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a Huntingtin (HTT) gene, as well as methods of inhibiting expression of an HTT gene and methods of treating subjects having an HTT-associated disease or disorder, e.g., Huntington's disease, using such dsRNAi agents and compositions.

WO 2022/212231 A2